Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

20141,316 citationsJournal Articlebronze Open Access

Authors

A. Keith Stewart · Mayo Clinic in Arizona

S. Vincent Rajkumar · Mayo Clinic in Arizona

Meletios Α. Dimopoulos · Alexandra Hospital

Tamás Masszi · Unified Szent István and Szent László Hospital

Ivan Špıčka

Albert Oriol · Hospital Universitari Germans Trias i Pujol

Roman Hájek · University of Ostrava

Abstract

In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Research on Leishmaniasis Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 2, pp. 142-152

DOI: 10.1056/nejmoa1411321

Field-Weighted Citation Impact: 76.44